News
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...
Albertans who want to continue to protect themselves from the COVID-19 virus will have to pay out of pocket for it starting in the fall of 2025, the province announced on Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback